Last reviewed · How we verify
Tezspire (TEZEPELUMAB)
Tezepelumab (Tezspire), co-developed by AstraZeneca and Amgen, is a marketed biologic for severe asthma, positioning it in a growing therapeutic segment. Its key strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics and biosimilars.
At a glance
| Generic name | TEZEPELUMAB |
|---|---|
| Sponsor | AstraZeneca / Amgen |
| Drug class | Thymic Stromal Lymphopoietin Blocker [EPC] |
| Modality | Monoclonal antibody |
| Phase | FDA-approved |
| First approval | 2021 |
Approved indications
- Severe Asthma
- Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Common side effects
- Pharyngitis
- Arthralgia
- Back pain
- Nasopharyngitis
Key clinical trials
- TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)
- Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea
- A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab (PHASE3)
- Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab (PHASE3)
- A Study for Observing Severe Asthma in Patients Treated With Tezepelumab
- Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA) (PHASE4)
- Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (PHASE3)
- EVOLVE Study: The Real-life Clinical Practice With Tezepelumab in Greece
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tezspire CI brief — competitive landscape report
- Tezspire updates RSS · CI watch RSS
- AstraZeneca / Amgen portfolio CI